Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya

Trial Profile

Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Artemether/lumefantrine (Primary) ; Artesunate/pyronaridine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 13 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 02 Nov 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top